Literature DB >> 22833757

Inpatient treatment of type 2 diabetes.

Thomas G K Breuer1, Juris J Meier.   

Abstract

BACKGROUND: Type 2 diabetes is common in hospitalized patients and is often accompanied by comorbidities; it is thus reasonable to ask whether the current standard treatments for type 2 diabetes are suitable for in-hospital use. We discuss the current glucose-lowering strategies and glycemic targets and derive practical recommendations for their application in hospitalized patients.
METHODS: The pertinent literature, including clinical trials, review articles, guidelines, and manufacturers' information is selectively reviewed.
RESULTS: In critically ill patients with diabetes, the glucose concentration target value should be 140 to 180 mg/dL. In stable patients, the target should be less than 140 mg/dL in the fasting state and less than 180 mg/dL after meals. Hypoglycemic episodes should be strictly avoided. Temporary treatment with insulin is indicated for most hospitalized patients with diabetes, although oral antidiabetic agents may be continued if the hospitalization is expected to be brief. Intravenous insulin is advisable in certain situations, e.g., long operations or metabolic decompensation. Glucose-lowering strategies must be chosen individually for each patient, with consideration of the relevant comorbidities (e.g. coronary heart disease, congestive heart failure, cirrhosis, renal failure) and special conditions (e.g. prolonged fasting, administration of contrast agents, high-dose glucocorticoid treatment).
CONCLUSION: The treatment of patients with type 2 diabetes in the hospital is very different from their treatment at home. The particular conditions and comorbidities that can arise in the hospital necessitate flexible, individualized strategies for lowering blood glucose concentration.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22833757      PMCID: PMC3401956          DOI: 10.3238/arztebl.2012.0466

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   5.594


  48 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study.

Authors:  G A Garinis; B Fruci; A Mazza; M De Siena; S Abenavoli; E Gulletta; V Ventura; M Greco; L Abenavoli; A Belfiore
Journal:  Int J Obes (Lond)       Date:  2010-02-23       Impact factor: 5.095

3.  Possible metformin-induced hepatotoxicity.

Authors:  Eiji Kutoh
Journal:  Am J Geriatr Pharmacother       Date:  2005-12

4.  Metformin in non-alcoholic steatohepatitis.

Authors:  G Marchesini; M Brizi; G Bianchi; S Tomassetti; M Zoli; N Melchionda
Journal:  Lancet       Date:  2001-09-15       Impact factor: 79.321

5.  Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.

Authors:  M Nowicki; I Rychlik; H Haller; M Warren; L Suchower; I Gause-Nilsson; K-M Schützer
Journal:  Int J Clin Pract       Date:  2011-10-07       Impact factor: 2.503

6.  Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients.

Authors:  M Shichiri; H Kishikawa; Y Ohkubo; N Wake
Journal:  Diabetes Care       Date:  2000-04       Impact factor: 19.112

7.  Newly detected glucose disturbance is associated with a high prevalence of diastolic dysfunction: double risk for the development of heart failure?

Authors:  R Füth; W Dinh; L Bansemir; G Ziegler; A Bufe; J Wolfertz; T Scheffold; Mark Lankisch
Journal:  Acta Diabetol       Date:  2009-03-11       Impact factor: 4.280

8.  Three-year efficacy of complex insulin regimens in type 2 diabetes.

Authors:  Rury R Holman; Andrew J Farmer; Melanie J Davies; Jonathan C Levy; Julie L Darbyshire; Joanne F Keenan; Sanjoy K Paul
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

9.  Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.

Authors:  Reinhard G Bretzel; Ulrike Nuber; Wolfgang Landgraf; David R Owens; Clare Bradley; Thomas Linn
Journal:  Lancet       Date:  2008-03-29       Impact factor: 79.321

10.  Implementation of a safe and effective insulin infusion protocol in a medical intensive care unit.

Authors:  Philip A Goldberg; Mark D Siegel; Robert S Sherwin; Joshua I Halickman; Michelle Lee; Valerie A Bailey; Sandy L Lee; James D Dziura; Silvio E Inzucchi
Journal:  Diabetes Care       Date:  2004-02       Impact factor: 19.112

View more
  7 in total

1.  [Requirements for the organization of pain therapy in hospitals: interdepartmental comparison for pain management from the employees' perspective].

Authors:  J Erlenwein; G Ufer; A Hecke; M Pfingsten; M Bauer; F Petzke
Journal:  Schmerz       Date:  2013-12       Impact factor: 1.107

Review 2.  [Pharmaceutical and insulin therapy of diabetes mellitus type 2. Update].

Authors:  E Siegel
Journal:  Internist (Berl)       Date:  2015-05       Impact factor: 0.743

3.  [Inpatient acute pain management in German hospitals: results from the national survey "Akutschmerzzensus 2012"].

Authors:  J Erlenwein; U Stamer; R Koschwitz; W Koppert; M Quintel; W Meißner; F Petzke
Journal:  Schmerz       Date:  2014-04       Impact factor: 1.107

Review 4.  [Treatment of type 2 diabetes].

Authors:  J J Meier
Journal:  Internist (Berl)       Date:  2016-02       Impact factor: 0.743

5.  Diabetes in the Hospital—A Nationwide Analysis of all Hospitalized Cases in Germany With and Without Diabetes, 2015-2017.

Authors:  Marie Auzanneau; Andreas Fritsche; Andrea Icks; Erhard Siegel; Reinhold Kilian; Wolfram Karges; Stefanie Lanzinger; Reinhard W Holl
Journal:  Dtsch Arztebl Int       Date:  2021-06-18       Impact factor: 5.594

Review 6.  The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes.

Authors:  Diethelm Tschöpe; Markolf Hanefeld; Juris J Meier; Anselm K Gitt; Martin Halle; Peter Bramlage; Petra-Maria Schumm-Draeger
Journal:  Cardiovasc Diabetol       Date:  2013-04-10       Impact factor: 9.951

Review 7.  Dose Modification of Antidiabetic Agents in Patients with Type 2 Diabetes Mellitus and Heart Failure.

Authors:  D C Sharma; Arthur Asirvatham; Parminder Singh
Journal:  Indian J Endocrinol Metab       Date:  2017 Jul-Aug
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.